3Sable CA;Nguyen BY;Chodakewitz JA.Safety and tolerability of caspofungin acetate in the treatment of fungal infections[J],2002(01). 被引量：1
4Colombo AL;Perfect J;DiNubile M.Global distribution and outcomes for Candida species causing invasive candidiasis:results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis[J],2003(08). 被引量：1
5Mora-Duarte J;Betts R;Rotstein C.Comparison of caspofungin and amphotericin B for invasive candidiasis[J],2002(25). 被引量：1
6Anon.Briefing document for voriconazole (oral and intravenous formulations),2001. 被引量：1
7Willems L;van der Geest R;de Beule K.Itraconazole oral solution and intravenous formulations:a review of pharmacokinetics and pharmacodynamics[J],2001(03). 被引量：2
8Strahilevitz J;Sugar AM;Engelhard D.Fluconazole in transplant recipients:options and limitations,2000(02). 被引量：1
9Hillbered PL;Rubin RH.Clinical aspects of fungal infections in organ transplant recipients,1994(z1). 被引量：1
10Girois SB;Chapuis F;Decullier E.Adverse effects of antifungal therapies in invasive fungal infections:review and meta-analysis[J],2005(02). 被引量：1
5Eida A J, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation[ J]. Drugs ,2010,70( 8 ) :965-81. 被引量：1
6Bonatti H, Pruett TL, Brandacher G, et al. Pneumonia in solid organ recipients: spectrum of pathogensin 217 episodes [ J ]. Transplant Proc,2009,41 ( 1 ) :371-374. 被引量：1
7AI-Hasan MN, Razonable RR, Eckel-passow JE, et al. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients[J].Transplant,2009,9 (4) :835-843. 被引量：1
8Einollahi B, Lessan-Pezeshki M, Pourfarziani V, et al. Invasive fungal infections following renal transplantation: a review of 2410 recipients [ J ]. Transplant,2008,13 (4) :55-58. 被引量：1
9Keven K, Sengul S, Memikoglu O, et al. Fatal outcome of disseminated invasive aspergillosis in kidney allograft recipients [J]. Med Mycol,2008,46 ( 7 ) :713. 被引量：1
